Accuray Incorporated (NASDAQ:ARAY) has been under a strong bear grip, hence the stock is down -3.63% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.28% in the past 1 week. The stock has risen by 1.57% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.08% in the past 4 weeks.
The company shares have dropped -27.51% from its 1 Year high price. On Nov 11, 2015, the shares registered one year high at $7.54 and the one year low was seen on Jul 7, 2016. The 50-Day Moving Average price is $5.25 and the 200 Day Moving Average price is recorded at $5.55.
The stock has recorded a 20-day Moving Average of 1.74% and the 50-Day Moving Average is 1.21%.
Accuray Incorporated (NASDAQ:ARAY): stock turned positive on Friday. Though the stock opened at $4.91, the bulls momentum made the stock top out at $5.2 level for the day. The stock recorded a low of $4.91 and closed the trading day at $5.19, in the green by 5.92%. The total traded volume for the day was 927,557. The stock had closed at $4.9 in the previous days trading.
In an insider trading activity, Levine Joshua, CEO of Accuray Inc, executed a transaction worth $356,000 on November 9, 2015. A total of 50,000 shares were purchased at an average price of $7.12. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures, sells and supports treatment solutions. Its suite of products includes the CyberKnife Systems and the TomoTherapy Systems. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy and adaptive radiation therapy. Its principal radiosurgery products, the CyberKnife Systems are robotic full-body radiosurgery system designed to treat tumors anywhere in the body non-invasively, which include the CyberKnife M6 Series with configuration options of fixed collimators plus iris variable aperture collimator, fixed collimators plus the InCise MLC and fixed collimators plus iris variable aperture collimator and the InCise MLC. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.